Drug resistance stands as a primary clinical hurdle in the effective management of MDS/AML patients, often arising during treatment with DAC, a prototypical DNMT inhibitor, consequently resulting in treatment failure [22, 23]. This evidence concerns the gene DNMT1 and acute myeloid leukemia.